Effect of chamomile oil in the treatment of carpal tunnel syndrome

Comparison of effectiveness of topical chamomile oil and placebo in the advancement of Boston questionnaire's score and electrodiagnostic criteria of patients with severe carpal tunnel syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014053011341N3

Enrollment

Registered

2014-06-24

Start date

2014-06-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal tunnel syndrome. Carpal tunnel syndrome

Interventions

Intervention 1: drug: chamomile oil, 5 drops, palmar wrist local use, morning and night-time, 4 weeks with wrist splint with 5 degrees extension for night-time use. Intervention 2: placebo:liquid para

Treatment - Drugs

Placebo

drug: chamomile oil, 5 drops, palmar wrist local use, morning and night-time, 4 weeks with wrist splint with 5 degrees extension for night-time use

placebo:liquid paraffin, 5 drops, palmar wrist local use, morning and night-time, 4 weeks with wrist splint with 5 degrees extension for night-time use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria: primary idiopathic carpal tunnel syndrome; patients aged between 18-70 years old; electrodiagnostic criteria for severe CTS; Patient's written informed consent for inclusion; having at least two signs or one sign plus one symptom of: paresthesias, numbness, tingling, night pain positive Phalen test, positive Tinnel test, positive compression test. Exclusion criteria: recurrent carpal tunnel syndrome; Positive history of trauma and/or fracture of wrist bones and/or surgical release of median nerve and/or direct injection into carpal tunnel of wrist; Evidence of cervical radiculopathy in EMG; Systemic disease including: neuropathies (rule out by nerve conduction study of ulnar nerves) and/or collagen vascular diseases such as SLE and scleroderma and RA; Endocrine diseases such as hypothyroidism and DM; Other disease-inducing neuropathy; Situations such as renal failure and/or alcoholism and/or poor medical condition; History of recent and ongoing use of corticosteroids or analgesics that could not be discontinued; hypersensitivity to the drug or placebo; inability to completion of data gathering forms (cognitive or language disorder).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Boston Carpal Tunnel Questionnaire score. Timepoint: beginning of the study and after 4 weeks. Method of measurement: Boston Carpal Tunnel Questionnaire.	—

Secondary

Measure	Time frame
Median nerve sensory distal latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Median nerve wrist sensory nerve conduction velocity. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Median nerve motor distal latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Median nerve compound latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Compound nerve action potential. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Grip power. Timepoint: beginning of the study and after 4 weeks. Method of measurement: dynamometry.;Median nerve sensory proximal latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.	—

Measure

Time frame

Median nerve sensory distal latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Median nerve wrist sensory nerve conduction velocity. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Median nerve motor distal latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Median nerve compound latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Compound nerve action potential. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.;Grip power. Timepoint: beginning of the study and after 4 weeks. Method of measurement: dynamometry.;Median nerve sensory proximal latency. Timepoint: beginning of the study and after 4 weeks. Method of measurement: electrodiagnosis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Hashem Hashempur

Shiraz University of Medical Sciences

hashempur@gmail.com+98 71 1233 7589

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026